Q-omics provides the consensus-scored CHCHD2P5 profile across patient tissues and cancer cell-line models. CHCHD2P5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CHCHD2P5 is differentially expressed in 3, with the highest sampling consensus in KICH. Additionally, CHCHD2P5 RNA expression shows 6,625 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KICH, and STAD as cancer lineages where CHCHD2P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHCHD2P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHCHD2P5 survival associations across molecular data types. CHCHD2P5 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHCHD2P5 RNA expression–survival associations across cancer types. High CHCHD2P5 expression shows unfavorable associations in UCEC, THCA, ACC, MESO, DLBC and LIHC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify UCEC as the clearest survival context for CHCHD2P5 RNA expression.
This table summarizes CHCHD2P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CHCHD2P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHCHD2P5 shows lower tumor expression in KICH and higher tumor expression in LIHC and PRAD. The KICH box plot shows higher CHCHD2P5 RNA expression in normal versus tumor tissue (log2 FC = −0.126, t-test p = .001).
This table shows molecular features associated with CHCHD2P5 in patient tissues and cancer cell lines. In patient samples, CHCHD2P5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
